0.12Open0.12Pre Close1 Volume0 Open Interest25.00Strike Price12.00Turnover88.53%IV43.38%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.0739Delta0.0354Gamma146.00Leverage Ratio-0.0116Theta0.0008Rho10.79Eff Leverage0.0063Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet